← Press Releases
JCN NewswireNovember 19, 2026 · 2h ago

Fujitsu Japan verifies utility of AI and U.S.-based Paradigm platform to streamline clinical trial candidate screening

KAWASAKI, Japan, November 19, 2026 - (JCN Newswire) - Fujitsu Japan Limited [1] (Fujitsu Japan), together with the National Cancer Center Hospital East [2] (NCCHE) and U.S.-based Paradigm Health, Inc. [3] (Paradigm), conducted joint research into the use of a Large Language Model (LLM) and Paradigm'

KAWASAKI, Japan, November 19, 2026 - (JCN Newswire) - Fujitsu Japan Limited [1] (Fujitsu Japan), together with the National Cancer Center Hospital East [2] (NCCHE) and U.S.-based Paradigm Health, Inc. [3] (Paradigm), conducted joint research into the use of a Large Language Model (LLM) and Paradigm's clinical trial matching platform, "Paradigm Platform" [4], to support the identification of potential candidates for clinical trials of new drugs. The research confirmed the effectiveness of the approach in significantly improving the efficiency of the candidate identification process.

Between June and the end of October 2026, the partners conducted a verification study using data from 22,334 patients in the Department of Respiratory Medicine, simulating a clinical trial targeting patients with EGFR gene [5] mutations. The process involved using an LLM to structure patient data from electronic medical records and linking this data to the "Paradigm Platform" for matching. As a result, it was confirmed that AI could identify 57 priority candidates along with the clinical evidence for these selections.

Building on the results of this research, Fujitsu Japan will proceed with the commercialization of a service to support the entire process from candidate screening to clinical trial enrollment, aiming for a launch by the end of fiscal year 2027. Through this service, the company aims to promote participation in clinical trials for new drugs and contribute to expanding treatment opportunities for patients.

Background

The issue of "drug loss," where new treatments available overseas are not developed or approved in Japan, is a pressing social challenge. To address this, there is an urgent need to promote clinical trials for new drugs. In recent years, personalized medicine based on genetic mutations and biomarkers [6] has advanced, particularly in oncology, making the criteria for clinical trial participation increasingly complex. Consequently, medical professionals must comprehensively review information dispersed across electronic medical records, treatment histories, test results, and genomic data. This places a significant burden on medical staff, not only affects the preparation and progress of clinical trials, but also serves as a factor in patients missing opportunities to consider new treatment options. Furthermore, differences in medical data formats and the prevalence of unstructured data in Japanese electronic medical records create obstacles for global data utilization.

Joint Research Overview

In this joint research, which began in June 2026, Fujitsu Japan, the NCCHE, and Paradigm utilized LLMs to structure unstructured data -such as patient medical records, treatment histories, and genomic information- necessary for clinical trial eligibility assessment [7]. This was then used to verify the application of the "Paradigm Platform," which has a proven track record in the United States.

Specifically, in a verification process simulating a clinical trial for patients with EGFR gene mutations, Fujitsu Japan performed data processing, including anonymization and structuring using LLMs, on electronic medical record information for 3,027 lung cancer patients out of 22,334 respiratory patients at the NCCHE, and linked this data to the "Paradigm Platform." Paradigm evaluated and matched the data of 540 patients among these 3,027 with EGFR gene mutations, based on five criteria used to determine clinical trial eligibility, successfully identifying 57 priority candidates. Subsequent review by physicians of the clinical records presented by the AI as evidence confirmed that 51 of these individuals were promising candidates.

Previously, clinical trial candidate identification relied on medical professionals—such as physicians and clinical research coordinators—to identify candidates and manually review individual medical records based on their own experience and knowledge. The results of this study confirmed that by utilizing AI and the "Paradigm Platform," medical institutions can comprehensively determine the eligibility of target patients for clinical trials based on standardized criteria, without relying on individual expertise. Furthermore, by identifying candidates through automated overnight processing, the system reduced the number of patient records requiring manual review by approximately 89%, demonstrating the potential to alleviate the burden on medical staff and expedite clinical trial opportunities for patients.

Figure : Joint Research Overview

Note: These results represent the candidates identified during this joint research and do not guarantee their actual participation in clinical trials. Final eligibility is determined by physicians based on trial requirements and the patient's consent.

Future Plans

Based on the results of this joint research, Fujitsu Japan aims to commercialize a service that supports the end-to-end process from clinical trial candidate identification to patient enrollment, with a target launch by the end of fiscal year 2027. Going forward, the partners will promote the adoption of this solution at medical institutions across Japan to help expand their capacity to conduct clinical trials. By providing more patients with opportunities to participate in clinical trials, Fujitsu Japan will contribute to faster clinical trial initiation and patient registration, ultimately facilitating broader access to new therapies.

Fujitsu Japan promotes the "Uvance" [8] business model, committed to achieving business transformation and creating social value through AI. The company will continue to use "Uvance" to streamline and advance clinical trials, aiming to eliminate drug loss and provide higher quality healthcare to every patient.

[1] Fujitsu Japan Limited:
Head office: Kawasaki, Kanagawa, Japan; Representative Director, CEO: Izuru Kokubu.
[2] National Cancer Center Hospital East:
Location: Kashiwa, Chiba, Japan; Hospital Director: Toshihiko Doi. A facility established and operated by the National Cancer Center.
[3] Paradigm Health, Inc.:
Head office: Columbus, Ohio, USA; CEO: Kent Thoelke.
[4] Paradigm Platform:
A clinical trial matching platform provided by Paradigm to support clinical trial operations, including patient population analysis, trial site selection, eligibility evaluation, and candidate identification.
[5] EGFR gene:
A gene that produces the EGFR protein. Mutations in this gene are significant indicators for treatment and clinical trial eligibility in conditions such as non-small cell lung cancer.
[6] Biomarker:
A biological indicator used to objectively evaluate disease status or response to treatment.
[7] Eligibility Assessment:
The process of verifying a patient's medical records against specific participation criteria for a clinical trial to determine if the patient meets those requirements.
[8] Uvance:
A business model committed to realizing customer transformation and creating social value in an era where AI is reshaping the world.

About Fujitsu

Fujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 100,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.5 trillion yen (US$23 billion) for the fiscal year ended March 31, 2026 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu

Press Contacts

Fujitsu Limited
Public and Investor Relations Division
Inquiries 




Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

Tokyo Overnight

Japan markets, decoded. Get the brief in your inbox.

No spam. Unsubscribe anytime.